GUARNERI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.249
AS - Asia 8.362
EU - Europa 6.381
AF - Africa 2.655
SA - Sud America 2.151
OC - Oceania 253
Continente sconosciuto - Info sul continente non disponibili 114
Totale 38.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.878
SG - Singapore 2.855
BR - Brasile 1.338
CN - Cina 1.251
HK - Hong Kong 1.246
IT - Italia 1.127
DE - Germania 764
FI - Finlandia 691
VN - Vietnam 403
PL - Polonia 342
SE - Svezia 319
FR - Francia 277
RU - Federazione Russa 248
NL - Olanda 243
IN - India 226
GB - Regno Unito 224
AR - Argentina 159
AT - Austria 143
TR - Turchia 137
KR - Corea 117
MX - Messico 112
ID - Indonesia 111
IE - Irlanda 108
IQ - Iraq 107
BJ - Benin 105
CI - Costa d'Avorio 105
EC - Ecuador 96
HU - Ungheria 94
ZA - Sudafrica 94
TN - Tunisia 92
AO - Angola 90
JP - Giappone 90
MK - Macedonia 90
PS - Palestinian Territory 90
PE - Perù 88
ES - Italia 86
UA - Ucraina 86
AE - Emirati Arabi Uniti 84
BE - Belgio 83
PA - Panama 83
CA - Canada 80
CZ - Repubblica Ceca 80
KE - Kenya 80
PH - Filippine 80
RS - Serbia 80
AZ - Azerbaigian 79
BA - Bosnia-Erzegovina 79
HN - Honduras 79
LC - Santa Lucia 79
NP - Nepal 79
UZ - Uzbekistan 78
CO - Colombia 77
GT - Guatemala 77
JO - Giordania 77
MA - Marocco 77
NO - Norvegia 76
LV - Lettonia 75
GH - Ghana 74
HR - Croazia 74
IL - Israele 73
BO - Bolivia 72
CL - Cile 72
CH - Svizzera 71
CY - Cipro 71
LB - Libano 71
MG - Madagascar 71
SA - Arabia Saudita 71
SI - Slovenia 71
PR - Porto Rico 70
BG - Bulgaria 69
DO - Repubblica Dominicana 69
LY - Libia 69
MZ - Mozambico 69
AL - Albania 68
BB - Barbados 67
BW - Botswana 67
CU - Cuba 67
IR - Iran 67
MD - Moldavia 67
MW - Malawi 67
YT - Mayotte 67
EG - Egitto 66
IS - Islanda 66
ME - Montenegro 66
MY - Malesia 66
PY - Paraguay 66
BY - Bielorussia 65
CV - Capo Verde 65
ML - Mali 65
NI - Nicaragua 65
PT - Portogallo 65
TT - Trinidad e Tobago 65
UG - Uganda 65
UY - Uruguay 65
ZW - Zimbabwe 65
JM - Giamaica 64
SN - Senegal 64
ZM - Zambia 64
BS - Bahamas 63
GM - Gambi 63
Totale 35.121
Salva come PNG Salva come JPEG
Città #
Fairfield 2.653
Singapore 1.713
Ashburn 1.707
Woodbridge 1.465
Houston 1.342
Hong Kong 1.168
Chandler 1.098
Ann Arbor 979
Seattle 893
Cambridge 884
Wilmington 791
Munich 493
Boardman 427
Helsinki 386
Beijing 342
San Diego 268
Santa Clara 262
Padova 260
Bytom 255
Medford 251
Princeton 251
Des Moines 209
Los Angeles 186
Hefei 146
Chicago 145
São Paulo 125
New York 118
Nanjing 117
Ho Chi Minh City 109
Roxbury 109
Dong Ket 102
Milan 102
Abidjan 100
Cotonou 96
Buffalo 82
Dublin 81
Pune 81
Castries 77
Nuremberg 77
Turku 75
Amman 74
Panama City 74
Vienna 74
Tashkent 72
London 71
Baku 70
Luanda 70
Antananarivo 66
Nairobi 65
Kampala 64
Lusaka 64
Accra 63
Conakry 62
Managua 62
Nassau 62
Bridgetown 61
Dakar 61
Podgorica 61
Harare 60
Redondo Beach 60
Seoul 60
Havana 59
Riga 57
Bamako 56
Dushanbe 56
Nouakchott 55
Reykjavik 55
Salt Lake City 55
Phnom Penh 54
Maputo 53
Montevideo 53
Libreville 52
Dallas 51
Kigali 51
Ulan Bator 51
Guangzhou 50
Lilongwe 50
Vientiane 50
Lima 49
Rome 49
San José 49
Skopje 49
Cayenne 48
Noumea 48
Praia 48
Yerevan 48
Bishkek 47
Kinshasa 47
Lappeenranta 47
Hanoi 46
Ouagadougou 46
Tripoli 46
Guatemala City 45
Minsk 45
Shenyang 45
Andorra la Vella 44
Niamey 44
Tbilisi 44
Willemstad 44
Amsterdam 43
Totale 23.330
Salva come PNG Salva come JPEG
Nome #
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 316
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 293
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 244
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 233
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 232
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 226
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 225
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 218
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 212
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 206
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 206
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 205
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 202
Immune characterization of breast cancer metastases: Prognostic implications 197
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 192
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 190
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 190
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 189
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 184
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 179
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 177
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 177
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 176
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 175
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 174
Escalation and de-escalation in HER2 positive early breast cancer 173
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 169
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 169
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 168
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 167
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 167
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 165
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 164
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 164
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 163
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 162
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 162
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 162
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 162
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 161
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 158
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 158
Evolution of HER2-low expression from primary to recurrent breast cancer 157
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 156
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 156
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 156
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 155
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 155
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 154
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 154
Achievements and unmet needs in the management of advanced ovarian cancer 152
Olaparib for the treatment of breast cancer 150
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 149
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 149
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 148
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 147
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 147
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 144
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 143
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 143
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 142
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 142
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 142
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 141
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 140
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 140
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 140
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 139
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 139
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 138
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 137
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 137
HER2-Positive Early Breast Cancer 136
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 136
Fat grafting for breast cancer patients: From basic science to clinical studies 135
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients 135
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 135
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 135
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 134
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 133
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 133
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 133
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 132
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 132
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 132
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 131
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study 131
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 130
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 130
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 130
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 130
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 129
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 129
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 128
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 127
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 126
Clinical utility of measuring circulating tumor cells in metastatic breast cancer 126
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 126
GD2 expression in breast cancer 126
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 126
Totale 16.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.706
article - articoli 125.924
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.883
Totale 256.513
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.505 0 0 0 0 135 549 296 196 372 368 271 318
2021/20223.568 155 396 432 199 306 246 284 273 215 116 263 683
2022/20232.371 483 225 109 279 319 248 48 148 325 35 118 34
2023/20241.683 100 194 161 121 103 237 129 90 92 79 178 199
2024/20257.943 25 529 312 250 817 304 478 810 789 410 1.220 1.999
2025/202613.982 1.312 2.438 4.662 5.433 137 0 0 0 0 0 0 0
Totale 38.601